The Sacral Nerve Stimulation Market is estimated to be valued at US$ 634.1 Mn in 2030

A newly published report by Coherent Market Insights reveals a sustainable growth opportunity in the sacral nerve stimulation market. Coherent Market Insights’ analyst projected the sacral nerve stimulation market to be valued at US$ 634.1 Mn in 2030. It is expected to exhibit a CAGR of 6% over the forecast period 2023 -2030.

The growing geriatric population is susceptible to overactive bladder which is one of the major drivers of the sacral nerve stimulation market. According to the United Nations, the number of persons aged 60 or over is expected to more than double by 2050 and more than triple by 2100.

Furthermore, technological advancements in sacral nerve stimulation devices have led to the development of minimally invasive procedures which reduce procedural time and post-operative care requirements. This has boosted the adoption of sacral nerve stimulation and fuelled market growth over the forecast period.

Key market trends include: The increasing preference for ambulatory surgical centers (ASCs) amongst healthcare providers as well as patients is a major trend in the sacral nerve stimulation market. Sacral nerve stimulation procedures can now easily be performed in ASCS due to the availability of minimally invasive techniques which help in shorter hospital stay and quicker recovery time.

Furthermore, rechargeable sacral nerve stimulator systems are gaining widespread acceptance in the market. These systems allow patients to recharge the implanted device using an external charging device thus increasing device longevity and reducing frequent replacements. This has increased patient compliance for sacral nerve stimulation therapy. 

Sacral Nerve Stimulation Market Opportunities: The sacral nerve stimulation market by product type is segmented into implantable SNS devices, external SNS devices, and accessories. Implantable SNS devices accounted for the largest market share in 2022, owing to the rising popularity of minimally invasive procedures and advantages associated with implantable devices such as patient comfort and convenience.

The sacral nerve stimulation market by application is segmented into urinary and faecal incontinence, chronic pain, and others. Urinary and fecal incontinence dominated the market in 2022 and is expected to maintain its dominance during the forecast period. This is owing to the growing incidences of urinary incontinence among the geriatric population coupled with the increasing adoption of SNS therapy for the treatment of urinary incontinence.

Key Market Takeaways: The global sacral nerve stimulation market is anticipated to witness a CAGR of 6% during the forecast period 2023-2030. This is owing to the rising prevalence of urinary incontinence and fecal incontinence across the globe.

On the basis of product type, implantable SNS devices segment is expected to hold a dominant position. This is owing to advantages such as patient comfort and convenience associated with implantable devices.

By application, urinary and fecal incontinence segment is expected to hold a dominant position over the forecast period. This is due to the growing incidences of urinary incontinence among the geriatric population.

On the basis of region, North America is expected to hold a dominant position over the forecast period. This is due to the growing geriatric population and rising demand for minimally invasive procedures in the region.

Competitor Insights: Key players operating in the sacral nerve stimulation market include Medtronic plc., Boston Scientific Corporation, Nevro Corp, StimWave Technologies Inc., Axonics, Inc., Synapse Biomedical, Uroplasty, St. Jude Medical, Cogentix Medical, and others.

Recent Developments: On February 22, 2022, the multinational healthcare technology company Medtronic plc declared that the next version of the InterStim portfolio’s recharge-free device, InterStim X, had been approved by the US Food and Drug Administration (FDA) and was now accessible. Furthermore, InterStim systems are the most individualized and the gold standard for advanced therapy alternatives when it comes to administering sacral neuromodulation (SNM) therapy. More information in full report